已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Abstract 3001: Highly selective and oral bioavailable PI3Kγ inhibitor for cancer immunotherapy by targeting myeloid-derived suppressor cells in tumor

癌症研究 髓样 医学 抑制器 癌症 免疫疗法 癌症免疫疗法 髓源性抑制细胞 内科学
作者
Hanning Wen,Shuai Mao,Mahamadou Djibo,Chengyi Li,Jinsong Tao,Hongyi Zhao,Qiyan Wang,Weijia Zheng,Bo Wen,Wei Gao,Duxin Sun
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:85 (8_Supplement_1): 3001-3001
标识
DOI:10.1158/1538-7445.am2025-3001
摘要

Abstract Introduction: Phosphoinositide 3-kinases (PI3Ks) are crucial for cell growth, survival, and metabolism, with dysregulated signaling common in cancer. The PI3K family includes four isoforms—PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ—each with distinct roles, where pan-PI3K inhibition often results in toxicity due to broad isoform expression. Existing various PI3K isoform inhibitors, despite in vitro specificity, often act as pan-inhibitors at high in vivo clinical effective concentrations (1μ M to 5μ M). We developed a highly selective PI3Kγ inhibitor that retains its specificity even at therapeutic in vivo levels, effectively targeting tumor immunosuppressive environment to inhibit tumor growth, while reducing toxicity associated with pan-PI3K inhibitions. Methods: Newly synthesized compounds were screened for PI3K isoform selectivity by kinase binding assays. After oral administration (p.o.), tissue distribution studies compared lead compounds with IPI-549 across various tissues, including tumor, spleen, tumor-draining lymph nodes (TDLNs), plasma and liver. The lead PI3Kγ inhibitors were further evaluated in vivo using MC38 colon cancer model and MMTV-PyMT breast cancer model, in both monotherapy (p.o.) and combination therapy with paclitaxel (PTX) or anti-PD-1 antibody (aPD-1). Immune cell profiling in tumor microenvironment was analyzed by flow cytometry post-treatment. Results: The lead compounds, SH-315 (γ IC50110.4nM, δ IC50>10000nM, β IC50>10000nM, α IC503212nM) and SH-327(γ IC50297.4nM, δ IC50>10000nM, β IC50 >10000nM, α IC502438nM), demonstrated significantly higher selectivity for PI3Kγ compared to IPI-549 (γ IC50 5.5nM, δ IC50 968.8nM, β IC50 1566nM, α IC50 1248nM). Concentrations of SH-315 and SH-327 were higher in target tissues (tumors, spleen, TDLNs), while plasma levels were lower than IPI-549, potentially reducing PI3K inhibitor-related side effects. In MMTV-PyMT model, SH-327 and SH-315 at 20 mg/kg, combined with PTX and aPD-1, led to significantly smaller tumors compared to IPI-549. In MC38 model, SH-315 at 10mg/kg combined with PTX and aPD-1 achieved Complete Response (CR) in 60% mice, where SH-327 at 20mg/kg achieved CR in 75% mice. SH-315 at 10mg/kg decreased CD11b+Ly6C+ myeloid-derived suppressor cells (MDSCs) in MC38 tumor by 24% compared to IPI-549 and increased CD8+ T cells in tumor by 41% than IPI-549, suggesting enhanced immune activation and reduced immunosuppression. Conclusion: The PI3Kγ inhibitors SH-315 and SH-327 demonstrated superior anti-tumor efficacy compared to IPI-549. Treatment with SH-315 and SH-327 reduced immunosuppressive MDSCs and increased cytotoxic CD8+ T cell activity, highlighting their potential to drive anti-tumor responses through targeted immune modulation and supporting their further development for cancer immunotherapy. Citation Format: Hanning Wen, Shuai Mao, Mahamadou Djibo, Chengyi Li, Jinsong Tao, Hongyi Zhao, Qiyan Wang, Weijia Zheng, Bo Wen, Wei Gao, Duxin Sun. Highly selective and oral bioavailable PI3Kγ inhibitor for cancer immunotherapy by targeting myeloid-derived suppressor cells in tumor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 3001.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
华仔的应助被狗熊岭在逃翠花采纳,获得10
刚刚
冷酷惠完成签到 ,获得积分10
刚刚
刚刚
小二郎的应助被三花大户采纳,获得10
3秒前
余叶发布了新的文献求助10
3秒前
科学心完成签到,获得积分10
4秒前
isabella完成签到,获得积分10
4秒前
4秒前
任性雁露发布了新的文献求助10
5秒前
5秒前
不易发布了新的文献求助10
5秒前
下北沢之兽完成签到 ,获得积分10
7秒前
CipherSage的应助被DW采纳,获得10
7秒前
李健完成签到,获得积分10
9秒前
hsj完成签到,获得积分10
10秒前
11秒前
11秒前
11秒前
Hunter完成签到,获得积分10
12秒前
12秒前
13秒前
三花大户发布了新的文献求助10
15秒前
K2C完成签到,获得积分10
16秒前
正直雪柳完成签到,获得积分20
16秒前
刻苦乐天发布了新的文献求助10
17秒前
姜OMG发布了新的文献求助10
17秒前
光亮的成败完成签到,获得积分10
17秒前
紫菜珍藏版完成签到 ,获得积分10
18秒前
科研通AI65的应助被DW采纳,获得10
19秒前
22秒前
姜OMG完成签到,获得积分10
23秒前
妖九笙完成签到 ,获得积分10
23秒前
imcwj完成签到 ,获得积分10
25秒前
小徐完成签到 ,获得积分10
25秒前
初景发布了新的文献求助10
26秒前
wnn完成签到,获得积分10
27秒前
dianxin完成签到,获得积分10
27秒前
28秒前
椰子水完成签到,获得积分10
28秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184889
求助须知:如何正确求助?哪些是违规求助? 9573836
关于积分的说明 21833242
捐赠科研通 7782263
什么是DOI,文献DOI怎么找? 3434429
关于科研通互助平台的介绍 2558581
邀请新用户注册赠送积分活动 2481082